SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02140333
 Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene 
      The purpose of this study is to determine whether 100mg erlotinib had similar effect compared
      with 150mg erlotinib in NSCLC patients with EGFR mutation in China.
    
NCT02140333  NSCLC  EGFR Mutation 
  1  Interventions 
 Name: Erlotinib
Description: 100mg vs. 150mg
 Type: Drug
Group Labels:  2  Erlotinib 100mg  Erlotinib 150mg  
  
Primary Outcomes 
 Measure: Progression free survival Time: 2 years after the initial dose
   
Secondary Outcomes 
 Measure: The objective response rate Time: Patients will be followed for an expected average of 6 months
   
Other Outcomes 
 Measure: Overall survival Time: 3 year after the initial dose
 Measure: Adverse events Time: 1 year
Purpose: Treatment
Allocation: Randomized
Parallel Assignment 
There is one SNP
SNPs
Inclusion Criteria:
          1. Histological diagnosis of NSCLC with phase IIIB or IV disease;
          2. Sensitive mutation EGFR gene (18, 19 del, 21 L858R gene mutation) (mutation detection
             methods:ARMS-PCR, sequence method)
          3. Never received anti-tumor therapies for the advanced stage;
          4. Never used EGFR inhibitors;
          5. Measurable disease by RECIST criteria;
          6. --- L858R ---